NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
New Drugs for Rheumatoid Arthritis | NEJM
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
NF-κB signaling in rheumatoid arthritis with focus on fibroblast-like synoviocytes | Autoimmunity Highlights | Full Text
Frontiers | LncRNAs and Rheumatoid Arthritis: From Identifying Mechanisms to Clinical Investigation
Frontiers | Pathomechanisms of bone loss in rheumatoid arthritis
Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis - Pharma Excipients
Leflunomide triggers ER stress and UPR in HepG2 cells. (A, B) Total... | Download Scientific Diagram
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
NF-kappaB: a key role in inflammatory diseases. - Abstract - Europe PMC
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma | HTML
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
Chemical structures of leflunomide and its metabolite A77 1726. | Download Scientific Diagram
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
Nuclear factor-κB: its role in health and disease | SpringerLink
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and Apoptosis | The Journal of Immunology
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis | Nature Communications
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells | Leukemia
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
Higher Levels of Leflunomide Are Associated with Hemolysis and Are not Superior to Lower Levels for BK Virus Clearance in Renal Transplant Patients | American Society of Nephrology
Leflunomide | C12H9F3N2O2 - PubChem
